Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Once Weekly Added to Basal Insulin Glargine in T2DM
NCT02229383Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Primary completion
- Aug 2016
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide QW with Placebo QW (2 arms). Primary endpoint: Change in HbA1c From Baseline at 28 weeks. Started Sep 2014; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02229383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229383.